



# Standard Guide for Determination of Purity, Impurities, and Contaminants in Biological Drug Products<sup>1</sup>

This standard is issued under the fixed designation E1298; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon ( $\epsilon$ ) indicates an editorial change since the last revision or reapproval.

## INTRODUCTION

The purity of biological drug products historically has been significantly lower than that of other pharmaceutical drug products. This is a consequence of the structural complexity of biological drug products as well as the fact that, until recently, these products were obtained only with great difficulty and at high cost from natural sources such as human or animal serum or tissue. Although many of these products were of low purity, long-term use in humans proved their safety and efficacy. The development of recombinant DNA (rDNA) technology and the parallel development of sophisticated preparatory, analytical, and immunological methods, have resulted in the ability to produce high purity biological drug products. It should be recognized that the standards for purity of rDNA-derived drugs are comparable to those established for United States Pharmacopeia (USP)-quality drug substances. For example, the purity of an rDNA-derived drug substance may exceed 97 % and impurities, (see Section 4) such as host cell proteins are separately quantitated in the parts per million range (via immunoassay).

## 1. Scope

1.1 This guide covers the concepts of purity, impurity, and contamination in biological drug products.

1.2 This guide suggests methods for determination of impurities and contaminants in such products.

1.3 This guide is arranged as follows:

	Section
Terminology	2
Significance and Use	3
Purity	4
General Considerations	4.1
Estimation of Purity	4.2
Impurities	5
General Considerations	5.1
Major and Minor	5.2
Nature and Consequences of	5.3
Contaminants	6
General Considerations	6.1
Effects of contaminants	5.2
Methods for Determining Impurities and Contaminants	7

1.4 *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appro-*

*priate safety and health practices and determine the applicability of regulatory limitations prior to use.*

## 2. Terminology

### 2.1 Definitions:

2.1.1 *contaminants*—all adventitious substances or microorganisms present in raw materials, bulk drugs, or final products.

2.1.2 *deleterious impurities*—impurities that might be a health or safety concern, particularly with respect to toxicity, carcinogenicity, or immunogenicity. Deleterious impurities must be controlled and their levels determined using suitable analytical methods.

2.1.3 *impurities, of a biological drug product*—all process-related (nonadventitious) substances present in the raw materials, bulk drug, or final drug product that are not considered to be the active material, additives, or excipients.

2.1.4 *innocuous impurities*—impurities that are not a health or safety concern in the product. The route of administration of the drug may be a significant criterion in the determination of whether an impurity is innocuous.

2.1.5 *purity, of a biological drug product*—the measure of the biologically active drug in relation to the total substances (not including additives) present in the drug product, usually expressed on a percentage basis.

<sup>1</sup> This guide is under the jurisdiction of ASTM Committee E55 on Manufacture of Pharmaceutical Products and is the direct responsibility of Subcommittee E55.04 on General Biopharmaceutical Standards.

Current edition approved Nov. 1, 2006. Published November 2006. Originally approved in 1998. Last previous edition approved in 2000 as E1298 – 98 (2000). DOI: 10.1520/E1298-06.

### 3. Significance and Use

3.1 This guide suggests analytical methods generally applied within the pharmaceutical industry to identify and quantify the level of impurities and contaminants present in the preparation of a biological drug product. These methods are not intended to be all-inclusive. The methods used by an individual manufacturer must be specific to the product and process of production.

### 4. Purity

4.1 *General Considerations*—Numerous considerations are involved in determining purity acceptability criteria, and these criteria are ultimately determined on a case-by-case basis. In each individual case, the risk-to-benefit ratio must be evaluated in determining an acceptable level of purity and the acceptable types of impurities of any new drug product. For example, the same purity requirements are not necessarily applied to a vaccine, which may be administered in one or two injections, as to a chronic care product, which may be administered several times per week for many years. It is not difficult with currently available technology to achieve a purity level of 97 % (w/w). At this level of purity, drug doses of 0.01, 0.1, and 1 mg/kg in a 70-kg patient correspond to impurities of 21 µg, 210 µg, and 2.1 mg/dose, respectively. At a purity of 99.99 %, these figures decrease to 0.07 µg, 0.7 µg, and 7 µg, respectively. Even these latter levels of impurities may be significant if they are repeatedly administered for prolonged periods. Although regulatory guidance on acceptable purity levels has been difficult to obtain, the lack of a database for rDNA-derived products has given rise to a generally more conservative approach than that which has been used previously for human biologics or blood-derived products. Also, the purity of a biological drug substance cannot be defined without specifying the assay method used. Various levels of purity may be obtained by a variety of analytical methods. It is, therefore, extremely important to use analytically valid methods for the estimation of purity.

4.2 *Estimation of Purity*—Purity may be estimated by two basic methods: weight percentage correlations or relative response measurements. A recognized reference standard is required for quantitation when using weight percentage methods while data may be obtained independently of a reference standard when using relative response measurements. However, the accuracy and precision of the latter type of measurement is usually less than that obtained using the reference standard technique. Relative response measurements are often employed for the measurement of unknown impurities for which no reference standard is available (see Table 1).

### 5. Impurities

5.1 *General Considerations*—Impurities may include substances derived from the active drug substance as well as nondrug-related components such as host cell proteins or nucleic acids. Impurities may include those proteins that have undergone a chemical or physical change at one or more sites in the molecule. The determination of whether such changes in a molecule result in impurities must be made based on data that demonstrate whether or not these molecules have the same,

**TABLE 1 Methods for Determination of Impurities and Contaminants**

Common Impurities or Contaminants	Detection Method
Endotoxin	LAL, <sup>A</sup> rabbit pyrogen, immunoassays, Massspectrometry
Host Cell Proteins	SDS-PAGE, <sup>B</sup> immunoassays
Other Protein Impurities	SDS-PAGE, HPLC, <sup>C</sup> immunoassays
Nucleic Acids	DNA hybridization, UV spectrophotometry, DNA sequencing, PCR, microarray
Mutants	HPLC-tryptic mapping, DNA sequencing, PCR, microarray, Massspectrometry
Formyl methionine	HPLC-tryptic mapping
Oxidized methionines	Amino acid analysis, HPLC-tryptic mapping, Edman degradation analysis, Massspectrometry
Proteolytic clips	IEF, <sup>D</sup> SDS-PAGE (reduced), HPLC, Massspectrometry
Deamidation	IEF (standard comparison), HPLC, Massspectrometry
Microbial (bacteria, yeast, and fungi)	Microbiological Testing (sterility, bioburden), immunoassays, DNA sequencing, PCR, microarray
Mycoplasmas	Modified 21CFR Method, <sup>E</sup> DNA <sup>F</sup> immunoassays, DNA sequencing, PCR, microarray
Viruses (endogenous and adventitious)	CPE, <sup>G</sup> Had, <sup>H</sup> electron microscopy, reverse transcriptase activity, immunoassays, Massspectrometry, DNA sequencing, PCR, microarray

<sup>A</sup> Limulus amoebocyte lysate.

<sup>B</sup> Sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

<sup>C</sup> High performance liquid chromatography.

<sup>D</sup> Isoelectric focusing.

<sup>E</sup> Draft guidelines.

<sup>F</sup> DNA binding fluorochrome.

<sup>G</sup> Cytopathic effect.

<sup>H</sup> Hemadsorption.

similar, or different properties compared to the intact drug molecule (see Table 1). The general considerations include the nature of the impurity, the amount of the impurity and the potential adverse effect of the impurity.

#### 5.2 Major and Minor Impurities:

5.2.1 Some distinctions have been made between major and minor impurities.<sup>2</sup> Although these distinctions were generated to address more conventional drugs, they are likely to form the basis for consideration of biological drugs, whose numbers will increase as rDNA products begin to reach the marketplace in larger numbers.

5.2.1.1 A major or significant impurity is one present at 0.5 to 1 % or greater. Levels of such an impurity should be kept as low as technically possible. The manufacturer may consider obtaining toxicologic, pharmacologic, and immunologic data on major impurities.

5.2.1.2 A minor impurity is one present at less than 0.5 %.<sup>2</sup> Recommended actions for impurities below this level are

<sup>2</sup> Wolters, R.J., "Bulk Drug Substances and Purity: A Regulatory Viewpoint," *Pharmaceutical Technology*, October 1984, pp. 35–38.

mainly concerned with identification. Identification (that is, molecular weight determinations) of minor impurities may be accomplished by utilizing some of the assays outlined in this guide or additional assays if necessary.

### 5.3 Nature of Impurities and the Consequences of Their Presence:

5.3.1 Because the products from rDNA are derived from living organisms, any host cell or host cell component is an impurity. In addition, other substances present during the growth of the organisms and purification of the product are impurities. Such substances include antibiotics, media, reagents, and column materials.

5.3.2 Impurities that may be associated with fermentation processes include proteins, nucleic acids, carbohydrates, lipids, and endogenous viruses. It is possible that these impurities may remain associated with the product and the characterization of the product should address this possibility.

5.3.3 Protein impurities are the most common impurities. These may arise from fermentation, media, or the host organism. The acceptable level of these impurities must be established based on toxicological and immunological studies.

5.3.4 Damaged, mutated, or modified product (for example, disulfide isomers) can result from either fermentation or handling during recovery. Because such substances may have altered pharmacokinetic properties, biological potency, or enhanced immunogenicity (potentially leading to antibodies against the product itself), these impurities could be of major concern. Characterization and quantitation of these impurities should address their pharmacology.

5.3.5 Concern about nucleic acid impurities arises from the possibility of cellular transformation events in a recipient. The use of eukaryotic cells as host cells for pharmaceutical production (whether using rDNA methods or not), has recently been examined in great detail and, by consensus, is acceptable if adequate testing is performed.<sup>3</sup> Part of this testing involves process and product characterization in removing host cell and vector DNA. In general, a process validation study that demonstrates DNA removal and provides final product analysis estimates of less than 10 pg/dose of host/vector DNA is both acceptable and achievable. Less or more stringent requirements may be needed in special cases.

5.3.6 Concerns related to viruses as impurities refer entirely to endogenous viruses that might be present in the host cell. Adequate characterization of the master cell bank and monitoring of the harvest supernatants together with well-designed and validated purification processes can identify and remove viral impurities. Incorporation of deactivation steps in the process is also desirable in order to achieve adequate safety margins even if such steps do not improve the product yield or purity.

5.3.7 Concerns related to adverse effect related to impurities refer to the effect of impurities on the functionality of the biological drug product (for example, competitive inhibition by

a dysfunctional mutant) or adverse effect not related to the biological drug product (for example, toxicity or allergenic). Incorporation of deactivation steps in the process is also desirable in order to achieve adequate safety margins even if such steps do not improve the product yield or purity.

## 6. Contaminants

6.1 *General Considerations*—Contaminants may be divided into biological adventitious agents and chemical adventitious agents.

6.1.1 Biological adventitious agents include bacteria, fungi, mycoplasmas, viruses, prions, and toxins.

6.1.2 Chemical adventitious agents include allergens and chemical species accidentally introduced into the material (for example, petroleum oil, heavy metals, residual solvents, column materials, cleaning reagents, and other products manufactured in the same facility).

### 6.2 Effects of Contaminants:

6.2.1 Contaminants may present a known health or safety risk. It is important to recognize that good manufacturing practices, (GMP) exist in the pharmaceutical industry to prevent or eliminate contaminants.

6.2.2 Contaminants may:

6.2.2.1 compromise host cell function prior to expression of the product,

6.2.2.2 cause degradation of the product after expression,

6.2.2.3 raise safety or efficacy issues if present in the final product, and

6.2.2.4 exist as a source of extraneous material, either innocuous or deleterious.

## 7. Methods for Determining Impurities and Contaminants

7.1 The methods outlined in **Table 1** are some of the methods that may be used to determine and quantify the level of impurities and contaminants present in a biological bulk drug substance or final product, or both.

7.2 Some methods are rather general in applicability, for example, limulus ameocyte lysate, (LAL) rabbit pyrogen, sterility testing, Masspectrometry, and electron microscopy. Many of these methods are general procedures used in many laboratories but they must be tailored to the specific product and process being evaluated. For example, the applicability of various high performance liquid chromatography, (HPLC) techniques may vary because of the size and hydrophobicity of the molecule being analyzed. It is also possible for manufacturers of similar or identical biological drug products to use entirely different manufacturing techniques and processes. These differences will probably necessitate the use of different assays to determine the level or presence of impurities and contaminants. In recent years the trend in bimolecular analysis is to use molecular methods such as DNA sequencing and PCR other trend includes the use of high throughput methods such as microarray and proteomics based methodologies such as LC-MS/MS. These methods have the potential to provide more detailed determination of purity, impurities, and contaminants in biological drug products.

<sup>3</sup> Quinnan, G.V., Jr., "Protein Contaminants in Biologic Products Derived from Cell Substances, in Abnormal Cells, New Products and Risk," *Proceedings*, National Institutes of Health, Bethesda, MD, 1985, p. 41.

*ASTM International takes no position respecting the validity of any patent rights asserted in connection with any item mentioned in this standard. Users of this standard are expressly advised that determination of the validity of any such patent rights, and the risk of infringement of such rights, are entirely their own responsibility.*

*This standard is subject to revision at any time by the responsible technical committee and must be reviewed every five years and if not revised, either reapproved or withdrawn. Your comments are invited either for revision of this standard or for additional standards and should be addressed to ASTM International Headquarters. Your comments will receive careful consideration at a meeting of the responsible technical committee, which you may attend. If you feel that your comments have not received a fair hearing you should make your views known to the ASTM Committee on Standards, at the address shown below.*

*This standard is copyrighted by ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959, United States. Individual reprints (single or multiple copies) of this standard may be obtained by contacting ASTM at the above address or at 610-832-9585 (phone), 610-832-9555 (fax), or [service@astm.org](mailto:service@astm.org) (e-mail); or through the ASTM website ([www.astm.org](http://www.astm.org)). Permission rights to photocopy the standard may also be secured from the ASTM website ([www.astm.org/COPYRIGHT/](http://www.astm.org/COPYRIGHT/)).*